
SPRINGER NATURE





springernature.com



ABOUT US

Biopharma Dealmakers is the premier publication for life scientists, biotech and pharmaceutical professionals, and investors looking for timely information on dealmaking and industry trends. For companies looking to showcase their innovations and expertise, we provide a range of strategic communication opportunities to reach your potential partners and investors.

Biopharma Dealmakers is published by Springer Nature, a leading publisher of scientific, medical, professional, and educational content.

Across our brands, we publish **3000+** journals and magazines - including *Nature*, the **#1** multidisciplinary science journal*.

FEATURED IN

Biopharma Dealmakers is featured quarterly in the journal editions of *Nature Biotechnology* and *Nature Reviews Drug Discovery.*


October 2021 Vol. 39 No. 10 nature biotechnology



#2 Journal in **BIOTECHNOLOGY & APPLIED MICROBIOLOGY***

cardiac pacemaker

nature reviews drug discovery



#1 journal in **BIOTECHNOLOGY & APPLIED MICROBIOLOGY***



AUDIENCE & REACH

AUDIENCE & REACH



NATURE BIOTECHNOLOGY

533,682 monthly page views*

253,843 monthly users*

324,514 monthly sessions*

NATURE REVIEWS DRUG DISCOVERY

410,994 monthly page views*

233,036 monthly users*

278,155 monthly sessions*

BIOPHARMA DEALMAKERS

15,453 monthly page views*

10,096 monthly users*

11,172 monthly sessions*

KEY AUDIENCE

BIOTECHNOLOGY 103 journals

22.3 MILLION monthly page views**

INFECTIOUS DISEASES



CANCER BIOLOGY

62 journals
21.9 MILLION
monthly page views**

IMMUNOLOGY



DRUG DEVELOPMENT



ONCOLOGY







PROFILES

Work with us to develop your profile article, to position your organization as an innovator in the biopharma industry, whilst discussing your novel technology platform or pipeline, and strategic business development goals.

Your article is created with expertise from our editorial team, with the full services of our writers, editors, and designers.

Your profile will be featured on:

- Our website on nature.com
- Quarterly digital issues
- Distributed within journal editions of Nature Biotechnology, Nature Reviews, Drug Discovery
- In our print publications distributed at key partnering conferences



BIOPHARMA THOUGHT LEADERS

PARTNERING: A KEY PILLAR BOLSTERING PFIZER'S INNOVATION PIPELINE

Pfizer's Centers for Therapeutic Innovation and other partnership initiatives champion emerging science and help stakeholders realize the potential of their innovations.

Successful drug development requires a rich and collaborative ecosystem involving many counterparts. It requires sharing information on everything from target selection to manufacturing platform technology, which drives researchers in biopharma, academia, start-ups, and biotech companies to collaborate. This joint vision keeps the landscape competitive as innovators seek precious opportunities to differentiate their offerings to prospective partners.

Pfizer, a leading company in the partnering space, offers a customized, two-pronged approach. One team focuses on partnering defined clinical assets. Another seeks cutting-edge, pre-clinical science and breakthrough technologies from academia, public-private partnerships and biotech. For the latter, identifying the most promising nascent external opportunities, matching them with the optimal collaboration vehicle to meet the diverse interests of potential partners, and translating these into robust drug development programs are among the key challenges.

Uwe Schoenbeck, Pfizer's Chief Scientific Officer for Emerging Science and Innovation (ES&I), said "Partnering is key for us, around 40% of our portfolio has been either externally sourced or critically enabled through partnerships. Securing clinical stage assets is critical for the short to midterm, but it is arguably just as important for an innovative biopharma to access cutting-edge science, breakthrough technologies and early-stage top quality assets to support our long-term success and leadership. We seek collaborations with academic medical centers and their investigators, and biotech companies in which both parties bring complementary capabilities to achieve something neither of us could do alone."

"To achieve this goal, Pfizer implemented a number of unique partnering vehicles, such as the Centers for Therapeutic Innovation (CTI)," added Schoenbeck, connecting internal resources and capabilities with academic discoveries to deliver a novel, transformative pipeline. CTI helps academic investigators navigate early translational



the complementary expertise of the PI and Pfizer researchers throughout the length of the project. Engaging PIs in the industrial drug development process with an experienced company like Pfizer is a significant attraction to many investigators." Each CTI project is led by a Pfizer scientific champion who uses internal research capabilities to address early translational challenges. CTI scientists engage from project conception to exit, ensuring transparent decision-making

dge science in col External innovati impact.These are

Pfizer's early-stage partnering model allows it to stay competitive in a rapidly evolving ecosystem, and to place strategic bets in emerging areas

Uwe Schoenbeck, Senior Vice President and Chief Scientific Officer Emerging Science & Innovation (ES&I)

Pfizer

and appropriate engagement of Pfizer enterprise resources, expertise and capabilities. "We have a portfolio of around 30 CTI projects at any given time," said Schoenbeck. "Pfizer has now advanced six CTI programs into the clinic, soon to be seven, of which three are in phase 2 clinical trials."

The CTI model is based out of four labs in New York, Boston, San Francisco and San Diego. Joe Dal Porto, Vice President and Head of CTI California, said "Through an open door policy, these labs

Emerging Science & Innovation: an external-facing partnering engine

Pfizer's Emerging Science and Innovation (ES&I) team is the dedicated partnering organization within Pfizer's Worldwide R&D and Medical (WRDM) organization, tasked with sourcing and advancing cutting-edge science in collaboration with academics and biotech. ES&I seeks:
External innovative technologies and early-stage opportunities that may yield near-term pipeline impact. These are sourced by *Emerging Science Leads (ESLs)* working in partnership with Business


View an example on **nature.com**



BRANDED CONTENT

Enhance the reach of your profile article with a highly targeted multichannel marketing to drive further engagement across our social media channels and related content.

We will work with you to build your campaign, develop advertisements, and social media posts.










WEBCASTS

Share your research and products in a real-time webinar and talk directly to your target audience. Generate actionable leads by downloading the webinar registrants list.

You choose the subject matter and presenters, while we take care of everything else, including: project management, promotion, and providing an experienced moderator.

Previous webcast topics have included:

- Making a name in cancer immunotherapy
- Advances in precision medicine and genomic sequencing
- Innovating for ophthalmic diseases



Example report

GDPR-compliant lead generation



Data collected on registrants' job functions, organization, and country

Up to **5 custom questions** can be added to your webcast registration page



Create branded content based on questions asked during your webcast's live Q&A session to address what your audience wants to hear more about.

4 ways to repurpose your custom webcast





DIGITAL ADVERTISING

Precisely target your banner ads using our three complementary targeting approaches.

Geographical targeting is available for all three options:



TARGET SPECIFIC JOURNALS



G

Target a journal or group of journals from our portfolio of 3000+ journals.

Nature Reviews Immunology, Nature Cancer





JOURNAL ADVERTISING

Biopharma Dealmakers is published quarterly in print, and is included in both the print and the digital PDF editions of Nature Biotechnology and Nature Reviews Drug Discovery. Your journal ad as well as your profile would benefit from being featured within the pages of these high impact Nature-branded publications.



SUBSCRIPTIONS*

737K print 8.5K digital SUBSCRIPTIONS*

763K print 5.8K digital



*Publisher Data, January-August 2021.



EDITORIAL CALENDAR 2022

Print & Digital

Issue date 2022	Editorial themes	Conference distribution (TBC)	Participation deadline
FEBRUARY – online Collection	Precision Medicine	BIO-Europe Spring (TBC)	26 th November 2021
	Molecular diagnostics & Next Generation Sequencing	American Association for Cancer Research (AACR) annual meeting (TBC, USA)	
		Bio-Trinity (TBC, London, UK)	
MARCH – full issue	Oncology	BIO-Europe Spring (TBC)	15 th December 2021
	Biopharma deals/Industry insights	American Association for Cancer Research (AACR) annual meeting (TBC, USA)	
		Bio-Trinity (TBC, London, UK)	
APRIL – online Collection	AI drug discovery (including AI spotlight)	Bio International Convention (TBC, USA)	4 th February 2022
MAY – online Collection	Infectious diseases and vaccines	Bio International Convention (TBC, USA)	3 rd March 2022
JUNE – full issue	Biopharma deals/Industry insights	Bio International Convention (TBC, USA)	18 th March 2022
	Cardio/metabolic		
JULY – online Collection	CNS	BioPharm America (TBC, USA)	4 th May 2022
		Bio-Europe (TBC, November)	
		Society for Neuroscience annual meeting (TBC, USA)	
SEPTEMBER – full issue	Immuno-oncology	BioPharm America (TBC, USA)	22 nd June 2022
	Antibody technologies	Bio-Europe (TBC, November)	
	Deals industry (TBC)	Society for Neuroscience annual meeting	





EDITORIAL CALENDAR 2022

Print & Digital

Issue date 2022	Editorial themes	Conference distribution (TBC)
OCTOBER – online Collection	Regen Med (cell & gene therapies)	JP Morgan/Biotech Showcase (2022 San Francisco, USA)
NOVEMBER – online Collection	Microbiome	JP Morgan/Biotech Showcase (2022 San Francisco, USA)
DECEMBER – full issue	Autoimmune diseases including inflammation-based-diseases and allergies	JP Morgan/Biotech Showcase (2022 San Francisco, USA)
	Animal health (TBC)	
	Deals round up of 2022	

Website

Monthly 2021	Topics	Topic summary
WEEK 1	Issue content	Our latest editorial and advertorial con editions.
WEEK 2	'Business of Science' digest Nature collection	A collection of the previous month's are portfolio related to pharmaceuticals, b investment and licensing.
WEEK 3	Deals round up	A comprehensive round-up of the majo month, categorized by parameters suc
WEEK 4	Biotech funding review	A review of the latest and major finance significant series A/B and any IPOs tied

Participation deadline

5th August 2022

6th September 2022

19th September 2022

intent showcased from the print

articles from the Springer Nature biotech, business, companies,

jor biopharma deals of the previous ich as value, or company.

icing rounds including details of any ed to current trends.







For more information on our marketing solutions, please contact your Account Manager or get in touch via:

Our website: partnerships.nature.com/contact-us

Claire Thompson Head of Business Development +44 788 003 2018 c.thompson@nature.com

Veronica Zacatenco

Business Development Manager +1 212 451 8573 veronica.zacatenco@us.nature.com

inkedin.com/showcase/biopharmadealmakersFollow twitter.com/@bpdealmakers

biopharmadealmakers



SPRINGER NATURE